Romain Varnier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Romain Varnier has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Denis Maillet
Department of Medical Oncology, Centre Hospitalier Lyon Sud, Institut de cancérologie des Hospices Civils de Lyon, Lyon, France; Department of Medical Oncology, Centre Hospitalier Lyon Sud, Institut de cancérologie des Hospices Civils de Lyon, Lyon, Jacques Lisfranc Medicine University, Saint-Etienne, France
3 shared publications - Emmie Goetz2 shared publications
- Ilhem Bensekka2 shared publications
- Inès Khati2 shared publications
- Isabelle Ray-Coquard
Centre Léon Bérard and Université Claude Bernard, Lyon, France
2 shared publications - Jean-Yves Blay
Medical Oncology Department Centre Léon Bérard Lyon France
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e89922
Patient-Centered Clinical Decision Support for Recommended Screenings in French Primary Care: Protocol for a Multicenter Mixed Methods Feasibility Study
Background: Primary care professionals (PCPs) are responsible for identifying eligibility and supporting patient decisions for a wide range of recommended screenings. However, the number of recommendations (42 for adults in France), complex eligibility criteria, limited consultation time, and competing priorities hinder their systematic delivery. Clinical decision support systems (CDSSs) with patient decision aids may help structure prevention-focused consultations and support shared decision-making, but their feasibility and acceptability in routine primary care remain uncertain. As part of the Aide aux Dépistages Recommandés (ADER) research program, we developed Lianeli, a CDSS designed to provide individualized, patient-centered support for all nationally recommended screenings. Objective: ADER-Faisabilité (ADER-F) is a study with the primary objective of assessing the feasibility of implementing Lianeli in routine primary care by estimating the proportion of patients for whom the CDSS is used to completion. Secondary objectives are to (1) quantitatively and qualitatively describe implementation feasibility, (2) describe organizational adjustments and interprofessional work related to the intervention, (3) explore the association between interprofessional use of Lianeli, health literacy, social deprivation, and feasibility, and (4 and 5) estimate the proportion of eligible, overdue or never screened patients who engage in organized or opportunistic cancer screening, respectively. Methods: ADER-F is a noncomparative, multicenter feasibility study with a mixed methods design conducted in primary care centers in the Auvergne-Rhône-Alpes region in France. We plan to recruit 210 adult patients from 21 general practitioners (GPs) across 17 sites. During routine consultations, eligible patients will be invited to complete a self-administered digital health questionnaire in Lianeli, which applies guideline-based algorithms to identify recommended screenings. Within 60 days, patients will attend a dedicated screening consultation during which the GP will validate the patient’s responses, discuss benefits and harms of each screening using shared decision-making, and update the patient’s screening pathway. Quantitative data will include Lianeli metadata, sociodemographic characteristics, health literacy, social deprivation, implementation feasibility measures (Guideline Implementation with Decision Support [GUIDES]–based questionnaires), and usability measures (French version of the System Usability Scale [F-SUS]). Semistructured interviews with patients and PCPs will be analyzed thematically and integrated with quantitative findings in a convergent metasynthesis. Results: The ADER-F study was funded in 2023. Following ethics approval in October 2025 and French National Commission on Data Protection authorization in February 2026, recruitment started in March 2026, with a planned 2-month inclusion period and an overall study duration of 6 months. The results are expected to be published in 2027. Conclusions: ADER-F will provide evidence on the feasibility and acceptability of a patient-centered CDSS to support recommended screenings in French primary care. The findings will identify determinants of successful implementation, guide possible developments of the Lianeli software and care pathways, and determine whether a subsequent effectiveness study is justified. Trial Registration: ClinicalTrials.gov NCT07270926; https://clinicaltrials.gov/study/NCT07270926 International Registered Report Identifier (IRRID): PRR1-10.2196/89922
- 3 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e89922
Open AccessPatient-Centered Clinical Decision Support for Recommended Screenings in French Primary Care: Protocol for a Multicenter Mixed Methods Feasibility Study
Background: Primary care professionals (PCPs) are responsible for identifying eligibility and supporting patient decisions for a wide range of recommended screenings. However, the number of recommendations (42 for adults in France), complex eligibility criteria, limited consultation time, and competing priorities hinder their systematic delivery. Clinical decision support systems (CDSSs) with patient decision aids may help structure prevention-focused consultations and support shared decision-making, but their feasibility and acceptability in routine primary care remain uncertain. As part of the Aide aux Dépistages Recommandés (ADER) research program, we developed Lianeli, a CDSS designed to provide individualized, patient-centered support for all nationally recommended screenings. Objective: ADER-Faisabilité (ADER-F) is a study with the primary objective of assessing the feasibility of implementing Lianeli in routine primary care by estimating the proportion of patients for whom the CDSS is used to completion. Secondary objectives are to (1) quantitatively and qualitatively describe implementation feasibility, (2) describe organizational adjustments and interprofessional work related to the intervention, (3) explore the association between interprofessional use of Lianeli, health literacy, social deprivation, and feasibility, and (4 and 5) estimate the proportion of eligible, overdue or never screened patients who engage in organized or opportunistic cancer screening, respectively. Methods: ADER-F is a noncomparative, multicenter feasibility study with a mixed methods design conducted in primary care centers in the Auvergne-Rhône-Alpes region in France. We plan to recruit 210 adult patients from 21 general practitioners (GPs) across 17 sites. During routine consultations, eligible patients will be invited to complete a self-administered digital health questionnaire in Lianeli, which applies guideline-based algorithms to identify recommended screenings. Within 60 days, patients will attend a dedicated screening consultation during which the GP will validate the patient’s responses, discuss benefits and harms of each screening using shared decision-making, and update the patient’s screening pathway. Quantitative data will include Lianeli metadata, sociodemographic characteristics, health literacy, social deprivation, implementation feasibility measures (Guideline Implementation with Decision Support [GUIDES]–based questionnaires), and usability measures (French version of the System Usability Scale [F-SUS]). Semistructured interviews with patients and PCPs will be analyzed thematically and integrated with quantitative findings in a convergent metasynthesis. Results: The ADER-F study was funded in 2023. Following ethics approval in October 2025 and French National Commission on Data Protection authorization in February 2026, recruitment started in March 2026, with a planned 2-month inclusion period and an overall study duration of 6 months. The results are expected to be published in 2027. Conclusions: ADER-F will provide evidence on the feasibility and acceptability of a patient-centered CDSS to support recommended screenings in French primary care. The findings will identify determinants of successful implementation, guide possible developments of the Lianeli software and care pathways, and determine whether a subsequent effectiveness study is justified. Trial Registration: ClinicalTrials.gov NCT07270926; https://clinicaltrials.gov/study/NCT07270926 International Registered Report Identifier (IRRID): PRR1-10.2196/89922
- 18 March 2026
- Published by Elsevier in Journal of Epidemiology and Population Health
- Vol. 74 (2) , 203364
Identifying cancer in the French National Health Data System (SNDS): an updated scoping review of algorithms, validation and applications
- 18 March 2026
- Published by Elsevier in Journal of Epidemiology and Population Health
- Vol. 74 (2) , 203364
Identifying cancer in the French National Health Data System (SNDS): an updated scoping review of algorithms, validation and applications
- 19 January 2026
- Published by S. Karger AG in Blood Purification
- Vol. 55 (3-4) , 161-170
Intraoperative Continuous Renal Replacement Therapy in Non-Cardiac, Non-Liver Transplantation Surgery: An Observational Cohort Feasibility Study
Introduction: Renal replacement therapy (RRT) is commonly used to manage metabolic disturbances in critically ill patients with acute kidney injury. While intraoperative RRT has been assessed in liver transplantation and cardiac surgery, its use in other surgical contexts remains unexplored. This study aimed to assess the feasibility of intraoperative continuous RRT (IoCRRT) in noncardiac, non-liver transplant surgeries. Secondary objectives included evaluating safety and describing the patient population. Methods: This retrospective study included all adult patients who underwent IoCRRT between January 2013 and January 2021 at Hospices Civils de Lyon (Lyon, France). Patients were classified as undergoing emergency or elective surgery. Data on IoCRRT indication, feasibility, safety, renal function at hospital discharge and mortality were analyzed. Results: IoCRRT was successfully implemented in all 43 patients. Severe acidosis (pH 90 mL/min/1.73 m2. Twenty-seven (63%) patients died within 30 days. Conclusion: IoCRRT seems to be a feasible and safe adjunctive therapy during emergency or elective surgery in patients with severe metabolic disorders. No IoCRRT-related complication was reported. Renal function appeared preserved. Further prospective studies are warranted to confirm these findings.
- 19 January 2026
- Published by S. Karger AG in Blood Purification
- Vol. 55 (3-4) , 161-170
Intraoperative Continuous Renal Replacement Therapy in Non-Cardiac, Non-Liver Transplantation Surgery: An Observational Cohort Feasibility Study
Introduction: Renal replacement therapy (RRT) is commonly used to manage metabolic disturbances in critically ill patients with acute kidney injury. While intraoperative RRT has been assessed in liver transplantation and cardiac surgery, its use in other surgical contexts remains unexplored. This study aimed to assess the feasibility of intraoperative continuous RRT (IoCRRT) in noncardiac, non-liver transplant surgeries. Secondary objectives included evaluating safety and describing the patient population. Methods: This retrospective study included all adult patients who underwent IoCRRT between January 2013 and January 2021 at Hospices Civils de Lyon (Lyon, France). Patients were classified as undergoing emergency or elective surgery. Data on IoCRRT indication, feasibility, safety, renal function at hospital discharge and mortality were analyzed. Results: IoCRRT was successfully implemented in all 43 patients. Severe acidosis (pH 90 mL/min/1.73 m2. Twenty-seven (63%) patients died within 30 days. Conclusion: IoCRRT seems to be a feasible and safe adjunctive therapy during emergency or elective surgery in patients with severe metabolic disorders. No IoCRRT-related complication was reported. Renal function appeared preserved. Further prospective studies are warranted to confirm these findings.
- Open Access
- 18 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Patient-Centered Clinical Decision Support for Recommended Screenings in French Primary Care: Protocol for a Multicenter Mixed Methods Feasibility Study (Preprint)
BACKGROUND Primary care professionals (PCPs) are responsible for identifying eligibility and supporting patient decisions for a wide range of recommended screenings. However, the number of recommendations (42 for adults in France), complex eligibility criteria, limited consultation time, and competing priorities hinder their systematic delivery. Clinical decision support systems (CDSSs) with patient decision aids may help structure prevention-focused consultations and support shared decision-making, but their feasibility and acceptability in routine primary care remain uncertain. As part of the Aide aux Dépistages Recommandés (ADER) research program, we developed Lianeli, a CDSS designed to provide individualized, patient-centered support for all nationally recommended screenings. OBJECTIVE ADER-Faisabilité (ADER-F) is a study with the primary objective of assessing the feasibility of implementing Lianeli in routine primary care by estimating the proportion of patients for whom the CDSS is used to completion. Secondary objectives are to (1) quantitatively and qualitatively describe implementation feasibility, (2) describe organizational adjustments and interprofessional work related to the intervention, (3) explore the association between interprofessional use of Lianeli, health literacy, social deprivation, and feasibility, and (4 and 5) estimate the proportion of eligible, overdue or never screened patients who engage in organized or opportunistic cancer screening, respectively. METHODS ADER-F is a noncomparative, multicenter feasibility study with a mixed methods design conducted in primary care centers in the Auvergne-Rhône-Alpes region in France. We plan to recruit 210 adult patients from 21 general practitioners (GPs) across 17 sites. During routine consultations, eligible patients will be invited to complete a self-administered digital health questionnaire in Lianeli, which applies guideline-based algorithms to identify recommended screenings. Within 60 days, patients will attend a dedicated screening consultation during which the GP will validate the patient’s responses, discuss benefits and harms of each screening using shared decision-making, and update the patient’s screening pathway. Quantitative data will include Lianeli metadata, sociodemographic characteristics, health literacy, social deprivation, implementation feasibility measures (Guideline Implementation with Decision Support [GUIDES]–based questionnaires), and usability measures (French version of the System Usability Scale [F-SUS]). Semistructured interviews with patients and PCPs will be analyzed thematically and integrated with quantitative findings in a convergent metasynthesis. RESULTS The ADER-F study was funded in 2023. Following ethics approval in October 2025 and French National Commission on Data Protection authorization in February 2026, recruitment started in March 2026, with a planned 2-month inclusion period and an overall study duration of 6 months. The results are expected to be published in 2027. CONCLUSIONS ADER-F will provide evidence on the feasibility and acceptability of a patient-centered CDSS to support recommended screenings in French primary care. The findings will identify determinants of successful implementation, guide possible developments of the Lianeli software and care pathways, and determine whether a subsequent effectiveness study is justified. CLINICALTRIAL ClinicalTrials.gov NCT07270926; https://clinicaltrials.gov/study/NCT07270926 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/89922
- 18 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPatient-Centered Clinical Decision Support for Recommended Screenings in French Primary Care: Protocol for a Multicenter Mixed Methods Feasibility Study (Preprint)
BACKGROUND Primary care professionals (PCPs) are responsible for identifying eligibility and supporting patient decisions for a wide range of recommended screenings. However, the number of recommendations (42 for adults in France), complex eligibility criteria, limited consultation time, and competing priorities hinder their systematic delivery. Clinical decision support systems (CDSSs) with patient decision aids may help structure prevention-focused consultations and support shared decision-making, but their feasibility and acceptability in routine primary care remain uncertain. As part of the Aide aux Dépistages Recommandés (ADER) research program, we developed Lianeli, a CDSS designed to provide individualized, patient-centered support for all nationally recommended screenings. OBJECTIVE ADER-Faisabilité (ADER-F) is a study with the primary objective of assessing the feasibility of implementing Lianeli in routine primary care by estimating the proportion of patients for whom the CDSS is used to completion. Secondary objectives are to (1) quantitatively and qualitatively describe implementation feasibility, (2) describe organizational adjustments and interprofessional work related to the intervention, (3) explore the association between interprofessional use of Lianeli, health literacy, social deprivation, and feasibility, and (4 and 5) estimate the proportion of eligible, overdue or never screened patients who engage in organized or opportunistic cancer screening, respectively. METHODS ADER-F is a noncomparative, multicenter feasibility study with a mixed methods design conducted in primary care centers in the Auvergne-Rhône-Alpes region in France. We plan to recruit 210 adult patients from 21 general practitioners (GPs) across 17 sites. During routine consultations, eligible patients will be invited to complete a self-administered digital health questionnaire in Lianeli, which applies guideline-based algorithms to identify recommended screenings. Within 60 days, patients will attend a dedicated screening consultation during which the GP will validate the patient’s responses, discuss benefits and harms of each screening using shared decision-making, and update the patient’s screening pathway. Quantitative data will include Lianeli metadata, sociodemographic characteristics, health literacy, social deprivation, implementation feasibility measures (Guideline Implementation with Decision Support [GUIDES]–based questionnaires), and usability measures (French version of the System Usability Scale [F-SUS]). Semistructured interviews with patients and PCPs will be analyzed thematically and integrated with quantitative findings in a convergent metasynthesis. RESULTS The ADER-F study was funded in 2023. Following ethics approval in October 2025 and French National Commission on Data Protection authorization in February 2026, recruitment started in March 2026, with a planned 2-month inclusion period and an overall study duration of 6 months. The results are expected to be published in 2027. CONCLUSIONS ADER-F will provide evidence on the feasibility and acceptability of a patient-centered CDSS to support recommended screenings in French primary care. The findings will identify determinants of successful implementation, guide possible developments of the Lianeli software and care pathways, and determine whether a subsequent effectiveness study is justified. CLINICALTRIAL ClinicalTrials.gov NCT07270926; https://clinicaltrials.gov/study/NCT07270926 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/89922
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (3) , 342-350
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board
PURPOSE: The management of immune-related adverse events (irAEs) requires multidisciplinary boards to handle complex cases. This study aimed to examine the evolving practices of the IMMUCARE board and to evaluate its impact on clinical practices. MATERIALS AND METHODS: The IMMUCARE board gathers oncologists and organ specialists from the Cancerology Institute of the Lyon University Hospital since 2018. We conducted a retrospective analysis of its activity (participants' specialty, referred cases, and recommendations) from 2018 to 2021, coupled with a survey among the physicians who participated. RESULTS: Across 68 board meetings, 245 cases from 195 patients were discussed. Each board had a median of six participants (IQR, 5-8). Participation rates varied across specialties and also over time (participation of nephrologists and rheumatologists significantly increased over time, whereas it decreased for endocrinologists). Most of the referred patients (89%) were treated at our center. Only 4% of referrals concerned eligibility for immune checkpoint inhibitor (ICI), whereas the majority pertained to irAEs. The board recommended ICI interruption for 56% and steroids for 41% of them. Immunosuppressants were recommended in 17% of cases, with a notable increase over time. ICI reintroduction was debated in 50% of cases, and the board identified a definitive contraindication in 26% of them. The survey of 49 of 98 physicians showed that the board significantly affected immunosuppressant introduction and ICI rechallenge decisions. The board's educational and collaborative benefits were highlighted, but time constraints posed challenges. CONCLUSION: Our 4-year analysis of irAE management practices reveals changing patterns in the distribution of cases presented and in specialists' involvement. Dedicated multidisciplinary boards remain essential, particularly for intricate cases. Expanding access to these boards is crucial to ensure comprehensive care for all patients.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (3) , 342-350
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board
PURPOSE: The management of immune-related adverse events (irAEs) requires multidisciplinary boards to handle complex cases. This study aimed to examine the evolving practices of the IMMUCARE board and to evaluate its impact on clinical practices. MATERIALS AND METHODS: The IMMUCARE board gathers oncologists and organ specialists from the Cancerology Institute of the Lyon University Hospital since 2018. We conducted a retrospective analysis of its activity (participants' specialty, referred cases, and recommendations) from 2018 to 2021, coupled with a survey among the physicians who participated. RESULTS: Across 68 board meetings, 245 cases from 195 patients were discussed. Each board had a median of six participants (IQR, 5-8). Participation rates varied across specialties and also over time (participation of nephrologists and rheumatologists significantly increased over time, whereas it decreased for endocrinologists). Most of the referred patients (89%) were treated at our center. Only 4% of referrals concerned eligibility for immune checkpoint inhibitor (ICI), whereas the majority pertained to irAEs. The board recommended ICI interruption for 56% and steroids for 41% of them. Immunosuppressants were recommended in 17% of cases, with a notable increase over time. ICI reintroduction was debated in 50% of cases, and the board identified a definitive contraindication in 26% of them. The survey of 49 of 98 physicians showed that the board significantly affected immunosuppressant introduction and ICI rechallenge decisions. The board's educational and collaborative benefits were highlighted, but time constraints posed challenges. CONCLUSION: Our 4-year analysis of irAE management practices reveals changing patterns in the distribution of cases presented and in specialists' involvement. Dedicated multidisciplinary boards remain essential, particularly for intricate cases. Expanding access to these boards is crucial to ensure comprehensive care for all patients.
- 8 May 2024
- Published by Elsevier in Bulletin du Cancer
- Vol. 111 (6) , 552-553
Les mots pour le dire